Galapagos beefs up its fibrosis pipeline, lassoing 4 more programs and taking a stake in small Canadian partner
The Belgian biotech has expanded a collaboration with Fibrocor Therapeutics — grabbing exclusive options to four more fibrosis programs and taking an equity stake in the company. Once Fibrocor completes the research work up to lead optimization, Galapagos may take over development.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 93,000+ biopharma pros reading Endpoints daily — and it's free.